Literature DB >> 15605672

Disseminated tuberculosis complicating anti-TNF-alpha treatment.

K Dimakou1, D Papaioannides, P Latsi, S Katsimboula, P Korantzopoulos, D Orphanidou.   

Abstract

An unusually large number of cases of tuberculosis, often of miliary or disseminated form, have been reported in patients receiving infliximab therapy for rheumatoid arthritis or Crohn's disease. We describe a patient with rheumatoid arthritis who was treated with infliximab and became systemically ill with Mycobacterium tuberculosis-disseminated infection. Patients who are candidates for treatment with tumour necrosis factor-alfa inhibitors should be evaluated for the presence of latent or active

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605672     DOI: 10.1111/j.1742-1241.2004.00061.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  12 in total

1.  Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.

Authors:  Philana Ling Lin; Amy Myers; Le'Kneitah Smith; Carolyn Bigbee; Matthew Bigbee; Carl Fuhrman; Heather Grieser; Ion Chiosea; Nikolai N Voitenek; Saverio V Capuano; Edwin Klein; JoAnne L Flynn
Journal:  Arthritis Rheum       Date:  2010-02

Review 2.  Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application.

Authors:  Jerrold R Turner
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 3.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

4.  IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction.

Authors:  Fengjun Wang; Brad T Schwarz; W Vallen Graham; Yingmin Wang; Liping Su; Daniel R Clayburgh; Clara Abraham; Jerrold R Turner
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

Review 5.  [Risk of infection during treatment with tumor necrosis factor-alpha inhibitors].

Authors:  A Gaemperli; T Hauser; R Speck
Journal:  Z Rheumatol       Date:  2006-02       Impact factor: 1.372

6.  Characterization and identification of distinct Mycobacterium massiliense extracellular proteins from those of Mycobacterium abscessus.

Authors:  A-Rum Shin; Hosung Sohn; Choul Jae Won; Byungsoo Lee; Woo Sik Kim; Hyun Bae Kang; Hwa-Jung Kim; Sang Nae Cho; Sung Jae Shin
Journal:  J Microbiol       Date:  2010-08-20       Impact factor: 3.422

7.  Cerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment.

Authors:  Karen Lynch; Michael Farrell
Journal:  Clin Rheumatol       Date:  2010-04-26       Impact factor: 2.980

8.  The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients.

Authors:  Ismail Hanta; Suleyman Ozbek; Sedat Kuleci; Ali Kocabas
Journal:  Clin Rheumatol       Date:  2008-03-05       Impact factor: 2.980

9.  Reactivation of M. tuberculosis infection in trans-membrane tumour necrosis factor mice.

Authors:  Ivy Dambuza; Roanne Keeton; Nasiema Allie; Nai-Jen Hsu; Philippa Randall; Boipelo Sebesho; Lizette Fick; Valerie J F Quesniaux; Muazzam Jacobs
Journal:  PLoS One       Date:  2011-11-21       Impact factor: 3.240

10.  Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab.

Authors:  Mehmet Unlu; Pınar Cimen; Aysu Ayranci; Tulay Akarca; Onur Karaman; Mustafa Sevket Dereli
Journal:  Respir Med Case Rep       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.